摘要
糖尿病患者罹患各类癌症的风险明显高于正常人,但其原因和机制仍不十分清楚,目前认为与高血糖、高胰岛素血症、胰岛素抵抗等因素相关。另外流行病学研究还提示糖尿病的治疗与癌症的发病率和死亡率有一定的关系,胰岛素或磺脲类药物因能增加体内胰岛素水平或加重胰岛素抵抗而使癌症风险增加,二甲双胍可能因为减轻胰岛素抵抗及血浆胰岛素水平而与癌症风险降低相关。本文就二甲双胍抗肿瘤分子机制的相关进展进行综述。
Compared with normal individuals, diabetic patients have a much higher risk of suffering from various kinds of cancer, however, the cause or underlying mechanism are not fully understood. It is generally believed that hyperglycemia, hyperinsulinemia and insulin resistance are highly related. Epidemiology study also showed that the application of insulin and sulfonylureas in diabetes therapy has also been associated with cancer incidence and mortality probably due to the increased plasma insulin level and the aggravated insulin resistance. Whereas, metformin could significantly reduce the risk of cancer by improving insulin resistance and decreasing plasma insulin level. This review will discuss the anti-cancer effects of metformin and the pleiotropic mechanism.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2014年第11期1241-1246,共6页
Cancer Research on Prevention and Treatment
基金
国家自然科学基金(30971082
81270482)
